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The prognosis of locally advanced hepatocellular carcinoma 
(HCC) patients with portal vein tumor thrombosis (PVTT) re-
mains dismal. Median survival time without treatment is only 
2.7 months.1 Transarterial chemoembolization (TACE) and 
chemotherapy have been used as palliation,2-5 and hepatic re-
section has been attempted as a curative measure, with less 
than satisfactory outcomes.5-8 Under these circumstances, liver 
transplantation has been considered a contraindication.9-11
Chapman, et al.12 have indicated that prolonged survival is 
achievable in this context through down-staging of HCC via 
neoadjuvant TACE and liver transplantation. Furthermore, Han, 
et al.13 recently reported an objective response rate of 45% us-
ing other modes of adjuvant treatment, such as localized con-
current chemoradiotherapy (CCRT), followed by hepatic arterial 
infusion chemotherapy (HAIC). Moreover, Lee, et al.14 recently 
reported surgical outcome of liver resection after down-stag-
ing of locally advanced HCC localized CCRT with 49.6% of 
5-year overall survival rate. Herein, we report our early experi-
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Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%. Localized 
concurrent chemoradiotherapy (CCRT), followed by hepatic arterial infusion chemotherapy (HAIC), was recently introduced in 
this setting. Here, we report our early experience with living donor liver transplantation (LDLT) in such patients after successful 
down-staging of HCC through CCRT and HAIC. Between December 2011 and September 2012, eight patients with locally ad-
vanced HCC at initial diagnosis were given CCRT, followed by HAIC, and underwent LDLT at the Severance Hospital, Seoul, Ko-
rea. CCRT [45 Gy over 5 weeks with 5-fluorouracil (5-FU) as HAIC] was followed by HAIC (5-FU/cisplatin combination every 4 
weeks for 3–12 months), adjusted for tumor response. Down-staging succeeded in all eight patients, leaving no viable tumor 
thrombi in major vessels, although three patients first underwent hepatic resections. Due to deteriorating liver function, trans-
plantation was the sole therapeutic option and offered a chance for cure. The 1-year disease-free survival rate was 87.5%. There 
were three instances of post-transplantation tumor recurrence during follow-up monitoring (median, 17 months; range, 10–22 
months), but no deaths occurred. Median survival time from initial diagnosis was 33 months. Four postoperative complications 
recorded in three patients (anastomotic strictures: portal vein, 2; bile duct, 2) were resolved through radiologic interventions. Us-
ing an intensive tumor down-staging protocol of CCRT followed by HAIC, LDLT may be a therapeutic option for selected patients 
with locally advanced HCC and portal vein tumor thrombosis. 
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ence of living donor liver transplantation (LDLT) in eight pa-
tients with locally advanced HCC and PVTT after successful 
down-staging of tumor through CCRT followed by HAIC. 
Diagnosis of HCC was based on either pathologic confirma-
tion or radiologic findings. Patients with unresectable HCC and 
PVTT in the main trunk or first order branch were indicated 
for CCRT following HAIC. Resectability was decided through 
regular multidisciplinary approach meeting by hepatobiliary 
surgeons, transplantation surgeons, hepatologists, radiologists, 
and radiation oncologists, based on patient’s liver function and 
radiologic image. To assess feasibility of LDLT, heaptobiliary 
surgeons and transplantation surgeons reviewed the degree 
and extent of portal vein thrombosis, checking for hepatic ar-
terial stricture or stenosis, as well as viability of extra-hepatic 
bile duct and the need for vascular or biliary reconstruction. In 
patients with locally advanced HCC and PVTT, localized CCRT 
was administered according to the standard protocol estab-
lished (1998) at Severance Hospital, Yonsei University College 
of Medicine, Seoul, Korea, followed by HAIC. This protocol 
has been described previously. Briefly, patients received a to-
tal radiation dose of 45 Gy in 25 fractions over a 5-week peri-
od, with concurrent HAIC of 5-fluorouracil (5-FU), 500 mg daily 
delivered via indwelling percutaneous hepatic arterial cathe-
ter during weeks 1 and 5 of radiotherapy. One month after lo-
calized CCRT, 5-FU (500 mg/m2 over 5 hours on days 1–3) and 
cisplatin (60 mg/m2 over 2 hours on day 2) were infused every 
4 weeks for 3–12 months, adjusting for tumor response.13 LDLTs 
were performed in eight consecutive patients who achieved 
successful down-staging of HCC by this means between De-
cember, 2011 and September, 2012. Upon approval of our In-
stitutional Review Board, data of all consecutive patients were 
collected.
Histopathology of explanted liver was evaluated by a single 
pathologist with appropriate expertise (YNP). Trans-abdomi-
nal Doppler ultrasonography was performed on days 1, 2, and 
4 post-transplantation to monitor the patency of hepatic and 
portal vascular anastomoses. Thereafter, dynamic multi-detec-
tor computed tomography (MDCT) was done on days 7, 14, 
and 21 post-transplantation, primarily to confirm patency of 
hepatic vessels and to monitor patients for potential postopera-
tive complications. As surveillance for tumor recurrence, MDCT 
was performed every 6 months during the first year post-trans-
plantation, then on a yearly basis. Tumor markers such as al-
pha-fetoprotein (AFP) and protein induced by vitamin K ab-
sence-II (PIVKA-II) were routinely checked each month. 
Disease-free survival rate was calculated by the Kaplan-Meier 
method with SPSS 20 for Windows (SPSS Inc., Chicago, IL, USA).
Each patient initially presented with locally advanced HCC 
and intrahepatic PVTT as well as active hepatitis B viral infec-
tion; and each was subjected to a regimen of CCRT, followed 
by HAIC, for tumor down-staging. All but one were male (me-
dian age, 46 years; range, 38–52 years). Three patients first un-
derwent hepatic resections (hemi-hepatectomies: left, 2; right, 
1), but intrahepatic recurrences developed in all three. TACE 
procedures, performed for tumor down-staging, had resulted 
in peribiliary necrosis (n=2) and liver failure (n=3). Semi-elec-
tive LDLTs were performed as life-saving treatment in these five 
patients, whose hepatic functions were rapidly deteriorating 
(Fig. 1).
Biologic and morphologic status of HCC improved after 
CCRT and other treatments. In all patients, serum tumor mark-
ers were initially quite high [AFP: median, 4418.07 ng/mL 
(range, 4.06–69912.95 ng/mL); PIVKA-II: median, 2000 mAU/
mL (range, 16–14044 mAU/mL)] but dropped dramatically pri-
or to LDLT [AFP: median, 26.87 ng/mL (range, 1.70–251.34 ng/
mL); PIVKA-II: median, 84.5 mAU/mL (range, 18–350 mAU/
mL)]. Median tumor diameter (at maximum) was 10.8 cm ini-
tially (range, 6.4–15.4 cm) by radiologic assessment, falling to 
3.8 cm (range, 1.3–9.0 cm) at post-transplantation pathologic 
examination (Fig. 2). No viable tumor was evident in the ex-
planted livers of two patients, indicating complete resolution 
of HCC after CCRT followed by HAIC (Table 1, Fig. 3).
Median post-transplantation follow-up monitoring was 17 
months (range, 10–22 months), and median survival time from 
initial diagnosis was 33 months (range, 22–48 months). No pa-
tient deaths occurred during the follow-up period, although 
three patients developed recurrent HCC at 4, 10, and 13 months 
post-transplantation as follows: multiple intrahepatic metas-
tases (patient 6, day 119), supraclavicular node metastasis (pa-
tient 4, day 294), and solitary lung metastasis (patient 1, day 
394) (Table 2). The lung and lymph node metastases were sur-
Fig. 1. Events leading to liver transplantation: overall, eight patients un-
derwent living donor liver transplantation (LDLT) after concurrent chemo-
radiotherapy, followed by hepatic arterial infusion chemotherapy. Ad-
vanced status of tumor (with portal vein tumor thrombosis) was initially 
down-staged via pre-transplant regimen. In five patients, transplanta-
tions constituted rescue therapy for hepatic decompensation. *The pa-
tient underwent LDLT after down-staging for recurred HCC without de-
compensated liver failure. CCRT, concurrent chemoradiotherapy; HAIC, 
hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma; 
PR, partial response.
Locally advanced HCC with 
portal vein tumor thrombus
(n=8)
CCRT followed HAIC
Radiologic PR
(n=2)
Liver resection
(n=3)
Decompensated liver failure (n=2)
Recurred HCC (n=1)*
Living donor liver transplantation
Decompensated liver failure
(n=3)
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gically resected with no further progression of disease. The pa-
tient with multiple intrahepatic metastases and portocaval 
lymph node metastasis underwent transcatheter arterial che-
moinfusion (TACI), followed by oral sorafenib (Nexavar®; Bay-
er Pharma AG, Berlin, Germany).
Intraoperative bleeding during LDLT was greater than expect-
ed, due to extensive adhesions and deteriorated states of perihe-
patic anatomy. Median intraoperative blood loss was 7550 cc 
Fig. 2. Radiologic tumor response (to concurrent chemoradiotherapy, followed by hepatic arterial infusion chemotherapy): computed tomography 
demonstrates bulky 12 cm hepatocellular carcinoma of right lobe (A), decreasing to 6 cm size, seen without enhancement in arterial phase (B). Volu-
minous ascites and splenomegaly developed, due to severe parenchymal atrophy and progressive hepatic dysfunction (B).
A B
Table 1. Biologic and Morphologic Responses before and after Liver Transplantation
Pt
Tumor marker response Initial radiologic findings Pathologic findings
Initial AFP Pre-LT AFP
AFP 
at last F/U
Initial 
PIVKA-II
Pre-LT 
PIVKA-II
PIVKA-II
at last F/U
Largest  
(cm)
Number
Largest 
(cm)
Viable 
tumor
1* 69912.95 42.88 11.65 2000 350 106 12.5 Multiple 2.8 (95% Nc) 3
2 356.21 4.06 2.96 16 58 14 9.6 4 1.3 1
3 3690.65 1.7 4.25 2000 166 15 15.4 2 6.5 (TNc) 0
4* 28754.5 40.52 1275.25 2000 46 888 12.0 2 4.8 (TNc) 0
5 5.3 13.21 4.39 468 21 731 7.0 1 1.5 (99% Nc) 1
6* 4.06 8.72 1.14 163 234 840 7.1 2 6.0 (TNc) 1
7 42166.28 202.27 287.02 2000 111 27 15.0 Multiple 9.0 (99% Nc) 4
8 5145.49 251.34 2.68 14044 18 23 6.4 1 1.4 (50% Nc) 2
AFP, α-fetoprotein (ng/mL); LT, liver transplantation; Nc, necrosis; PIVKA-II, protein induced by vitamin K absence-II (mAU/mL); Pt, patient; TNc, total necrosis. 
*Recurrence after liver transplantation.
Fig. 3. Gross and microscopic views of liver specimen: note expansile necrotic mass 4.8 cm in size, with diffuse macronodular parenchymal cirrhosis 
(A). At high magnification, complete necrosis of hepatocellular carcinoma (near asterisk), inflammatory change (near arrow), and normal hepato-
cytes (near arrowhead) are observed (B; hematoxylin and eosin stain, ×100).
A B
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(range, 2500–12200 cc). Patient 2 had suffered peribiliary ne-
crosis prior to transplantation, resulting in significant hilar re-
structuring (i.e., portal vein anastomosis, using preserved iliac 
artery conduit; anastomosis of hepatic artery, with autologous 
middle colic artery interposition; and Roux-en Y hepaticojeju-
nostomy for anastomosis of bile duct). Five of eight patients 
required unconventional hepatic artery anastomoses, using 
autologous arterial interposition or transposition graft. In three 
patients, Roux-en Y hepaticojejunostomy was done for bile duct 
reconstruction. Ultimately, four complications related to anasto-
moses were recorded in three patients (bile duct stricture, 2; 
portal vein stenosis, 2) (Table 3). All complications were suc-
cessfully resolved through radiologic interventions.
Liver transplantation is considered one of the best treatment 
options for patients with early-stage HCC.15-17 However, this 
accounts for only 10–20% of those with HCC overall. The major-
ity of sufferers have more advanced disease.18 Various down-
staging procedures, including radiofrequency ablation, TACE, 
TACI, and transarterial radioembolization with Yttrium-90 mi-
crospheres (TARE-Y90), have been devised for advanced 
HCC.10,12,18-21 However, recent use of liver transplantation after 
successful down-staging of tumors has yielded acceptable re-
sults compared with outcomes of liver transplantation in ear-
ly-stage HCC and in end-stage liver disease.22-24 
TACE or TARE-Y90 are viewed as a relative contraindications 
in patients with advanced HCC and PVTT, because conven-
tional down-staging protocols have had negligible success.25 
Using a regimen of localized CCRT followed by HAIC in precise-
ly such patients, who were unresponsive to conventional thera-
py, Han, et al.13 showed a substantial response rate (45%) and an 
acceptable median survival time (13.1 months). Localized ra-
diotherapy (RT) of the liver has also emerged as an effective 
means of controlling the progression of HCC, compared with 
whole-liver RT.26 Highly selective localized RT enables more 
intense targeting of masses in liver, with less hepatotoxicity.
Conventional systemic chemotherapy has proven ineffec-
tive in HCC, and toxicity is an issue. However, HAIC allows local 
delivery of chemotherapeutic agents in greater concentrations, 
alleviating systemic toxicity.2,27-29 With concurrent use of hepat-
ic RT and HAIC, response rates in patients with locally advanced 
HCC stand to improve, although roughly a 30% rate of hepatic 
decompensation has been reported with the use of CCRT fol-
lowed by HAIC in this setting.13
Generally, patients with locally advanced HCC and PVTT 
have been ineligible for liver transplantation, even with down-
staging, due to high rates of tumor recurrence.9-11 Earlier, we per-
Table 3. Perioperative Conditions of Patients
Pt Sex/age MELD
Pre-LT treatment Transfusion 
of pRBC
Uncommon anastomosis
Postop Cx
CCRT TACE or TACI Liver resection PV HA BD
1 M/46 12 + + - 5 BD stricture
2 F/48 22 + + + 15 Iliac a. conduit MCA inter. RY PV stricture
3 M/52 12 + - - 10 MHA PV & BD stricture
4 M/45 7 + + - 7 RGEA trans. RY
5 M/44 7 + + - 0
6 M/38 9 + + + 11
7 M/51 8 + + - 5 LGA trans. RY
8 M/52 7 + + + 5 RGEA trans.
BD, bile duct; CCRT, concurrent chemoradiotherapy; HA, hepatic artery; iliac a., iliac artery; inter., interposition; LGA, left gastric artery; LT, liver transplantation; 
MCA, middle colic artery; MELD, model for end-stage liver disease score; MHA, middle hepatic artery; Postop Cx, postoperative complication; pRBC, packed red 
blood cell (unit); PV, portal vein; RGEA, right gastroepiploic artery; RY, Roux-en Y hepaticojejunostomy; TACE, transarterial chemoembolization; trans., transposi-
tion.
Table 2. Survival Outcomes after Living Donor Liver Transplantation
Patients
Survival time  
(from initial diagnosis)
Follow-up duration 
(post-transplant)
Mortality Recurrence
Time to recurrence after 
liver transplantation
Site of recurrence
1 28 22 - + 13 Lung
2 48 21 - -
3 48 18 - -
4 34 17 - + 10 Supraclavicular node
5 28 17 - -
6 44 14 - + 4 Liver, portocaval lymph node
7 32 13 - -
8 22 10 - -
Median value 33 17
Numerical values expressed in months.
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formed LDLTs as life-saving interventions in five patients, who 
suffered from rapid hepatic functional deterioration after CCRT 
and HAIC. Given satisfactory short-term outcomes in these ini-
tial five attempts, we then performed LDLTs in another three 
patients, who achieved down-staging of HCC. No mortalities 
occurred during the follow-up periods, and the 1-year disease-
free survival rate was 75.0%. 
There are two critical factors in this group of patients, in 
terms of eligibility for LDLT. The first issue is operative feasibil-
ity, which is often hampered by significant anatomic deterio-
ration after various down-staging procedures, including RT, 
HAIC, and other treatments (e.g., TACE or liver resection). Radi-
ation alone is known to damage the microvasculature and in-
duce hepatic fibrosis.30 Moreover, HAIC and TACE create sig-
nificant hepatic hilar inflammation and intimal arterial injury, 
and their inflict may result in vascular thrombosis, adding to ra-
diation effect.18,31 In this particular group of patients, LDLTs are 
demanding procedures, subject to elaborate preoperative prep-
aration. 
Only three of our eight patients were suited for conventional 
anastomoses of hilar structures. Modifications were otherwise 
required for reconstruction of hepatic vessels and biliary drain-
age. In patient 2, cryopreserved iliac artery was used as a con-
duit for portal vein anastomosis (due to thrombosis); hepatic 
artery anastomosis required autologous middle colic artery 
interposition graft (due to stenosis); and Roux-en-Y hepaticoje-
junostomy was performed for bile duct reconstruction. These 
types of complex and technically demanding anastomoses in 
damaged areas resulted in some postoperative complications: 
in three patients, a total of two portal vein and two bile duct 
strictures developed at anastomotic sites, but all complications 
were resolved through radiologic interventions. Nevertheless, 
reconstruction of vascular and biliary system was feasible, and 
all complications were resolved through radiologic interven-
tions. Thus, LDLTs are not off-limits in these patients.
The second critical issue is the achieved degree of tumor 
down-staging. For survival of both patient and graft, successful 
down-staging of HCC is a prerequisite, as determined by radio-
logic and biologic response to treatment. Tumor necrosis and 
change in tumor size on imaging studies are the indices of radio-
logic response. Biologic response is evaluated by declining levels 
of serum tumor factors, such as AFP and PIVKA-II. In most pub-
lished studies, an acceptable serum AFP level is <400 ng/mL, 
which all of our patients displayed. Median pre-transplanta-
tion serum AFP level was 26.87 ng/mL (range, 1.7–251.34) (Ta-
ble 1). 
There were three instances of tumor recurrence during post-
transplantation follow-up periods (Table 2). Two patients (soli-
tary pulmonary nodule and supraclavicular node metastasis, 
respectively) were treated by surgical resection, with no further 
disease progression. The remaining patient, showing multiple 
intrahepatic metastases, underwent TACI, followed by adju-
vant sorafenib. Unfortunately, portocaval lymph node metas-
tasis then presented. In patients with locally advanced HCC, 
chances of systemic recurrence after liver transplantation are ac-
tually quite high.15,32,33 Thus, early detection of tumor recurrence 
and active treatment might be important for survival in these 
patients. Although one study has addressed the utility of adju-
vant treatment for HCC after liver transplantation, controversy 
persists.34 The recurrence pattern and prognosis will be further 
analyzed in future with agents of choice for adjuvant use.
This is the first-ever report of successful consecutive LDLTs 
in patients with locally advanced HCC and PVTT, after down-
staging by using CCRT and HAIC. Nevertheless, appropriate pa-
tient selection, proper timing of transplants, and effective post-
transplantation adjuvant therapy should be further investigated 
on a larger scale in a randomized controlled study. In the present 
study, median patient and graft survival of 33 months (range, 
22–48 months) was achieved after initial diagnosis of HCC, 
compared with an expected 1-year survival of <10%.1,35,36
In conclusion, acceptable oncologic outcomes and short-
term survival times are achievable in patients with locally ad-
vanced HCC and PVTT, using a down-staging regimen of CCRT 
followed by HAIC. However, long-term outcomes have yet to be 
determined. 
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